Octacosane-d58

Octacosane-d58 is the deuterium labeled Octacosane[1]. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l[2][3][4].

Product Specifications

CAS Number

[16416-33-4]

Product Name Alternative

N-Octacosane-d58; NSC 5549-d58

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Bacterial; Endogenous Metabolite

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer

Purity

99.05

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H]

Molecular Formula

C28D58

Molecular Weight

453.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Carlos R Figueiredo, et al. Pyrostegia venusta heptane extract containing saturated aliphatic hydrocarbons induces apoptosis on B16F10-Nex2 melanoma cells and displays antitumor activity in vivo. Pharmacogn Mag. 2014 Apr;10 (Suppl 2) :S363-76. |[3]S Rajkumar, et al. Mosquitocidal activities of octacosane from Moschosma polystachyum Linn (lamiaceae) . J Ethnopharmacol. 2004 Jan;90 (1) :87-9.|[4]Sameh S M Soliman, et al. Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites. PLoS One. 2020 Oct 6;15 (10) :e0240156.